1-2 of 2
Lidwine Tick
Close
Sort by
Journal Articles

Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study

Clinical Trials & Observations
Marco Herling, Claire Dearden, Francesco Zaja, Dima El-Sharkawi, Wei Ding, Mar Bellido, Amit Khot, Lidwine Tick, Eric Jacobsen, Toby A. Eyre, Damien Roos-Weil, Tapan Kadia, Elisa Lucchini, Natali Pflug, Matthew S. Davids, German Pena, Nabanita Mukherjee, Mohamed Badawi, Tamas Vizkelety, Philipp B. Staber
Journal: Blood Advances
Blood Adv (2024) 8 (4): 842–845.
https://doi.org/10.1182/bloodadvances.2023012248
Published: 2024
Includes: Supplemental data
Journal Articles

Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS

Clinical Trials & Observations
Gerwin Huls, Dana A. Chitu, Thomas Pabst, Saskia K. Klein, Georg Stussi, Laimonas Griskevicius, Peter J. M. Valk, Jacqueline Cloos, Arjan A. van de Loosdrecht, Dimitri Breems, Danielle van Lammeren-Venema, Isabelle van Zeventer, Rinske Boersma, Mojca Jongen-Lavrencic, Martin Fehr, Mels Hoogendoorn, Markus G. Manz, Maaike Söhne, Rien van Marwijk Kooy, Dries Deeren, Marjolein W. M. van der Poel, Marie Cecile Legdeur, Lidwine Tick, Yves Chalandon, Emanuele Ammatuna, Sabine Blum, Bob Löwenberg, Gert J. Ossenkoppele
Journal: Blood Advances
Blood Adv (2020) 4 (18): 4267–4277.
https://doi.org/10.1182/bloodadvances.2020002846
Published: 2020
Includes: Supplemental data